Dr. Evgeny Zaytsev

Biography

As well as participation in management of RMI Partners, Evgeny has been a member of the Board of Directors of Clearside Biomedical, Atea Pharmaceuticals, Epic Sciences, NovaDigm Therapeutics, Tragara Pharmaceuticals and Transcend Medical. Evgeny has a successful track record as a venture capitalist with more than 20 years of experience of investing in biomedical technologies. He is a co-founder and general partner at Helix Ventures (Palo Alto, California) – an investment company focused on innovative therapeutic technologies (biopharmaceuticals and medical devices). Previously Evgeny was a partner of Franklin ‘Pitch’ Johnson, a pioneer of venture capital industry, at Asset Management Company, one of the oldest venture firms in the Silicon Valley. Evgeny’s professional portfolio includes more than 30 investments in biomedical companies, including a number of high-profile venture capital success stories, such as BiPar Sciences (acquired by Sanofi-Aventis), Chimerix (IPO NADSDAQ: CMRX), Enteric Medical Technologies (acquired by Boston Scientific), Fusion Medical Technologies (acquired by Baxter International),MicroVention(acquired by Terumo Corporation)and Coherus Biosciences (NASDAQ: CHRS). At the start of his career Evgeny was deputy director for science at the Institute of Regional Medico-Ecological Problems in Barnaul, the leading institute of the federal research programme Semipalatinsk Nuclear Test Site – Altai, which investigated the consequences of nuclear tests for human health and the environment. During his seven years in this position, the institute was transformed into a globally recognised research centre for its work on investigating the impact of radioactive exposure for human health. Evgeny is an active leader of the business community and the venture capital industry in Russia and the Silicon Valley. He was one of the founders and first president of US-Russia Technology Symposium at Stanford University (now the Global Technology Symposium), and the annual Silicon Valley Open Doors investment conference. Evgeny is the author of more than 70 scientific and business publications on entrepreneurship, venture capital and biotechnologies. Evgeny graduated from Altai State Medical University(Russia)cum laude in 1991 and earned his Ph.D. in Physiology from the same university in 1993. He earned his M.B.A. from the Stanford Graduate School of Business (California) in 2002.

Research Interest

Clearside Biomedical, Atea Pharmaceuticals, Epic Sciences, NovaDigm Therapeutics, Tragara Pharmaceuticals and Transcend Medical.